Copy
 
 
 
 

Looking Back at COMBACTE General Assembly 2017

 

This year’s COMBACTE General Assembly Meeting took place on March 14-16 in the historic and muticultural city of Brussels, Belgium. Once again, the General Assembly hosted a great 195 attendees from 13 countries.

 
Read full article
 
 
 
 
 
alt text
 
 

ECCMID 2017 Highlights: COMBACTE's Scientific Coordinator, Marc Bonten

 

Prof. Dr. Marc Bonten, scientific coordinator and Management Board member of the IMI-funded COMBACTE consortium, talks about his path to microbiology and the importance of ECCMID for COMBACTE.This year COMBACTE will be present once again at the ECCMID in the exhibition hall, and will host its 5th consecutive Investigators Meeting.

 
Read full article
 
 
 
 
 
 
 

Looking Back: CLIN-Net and LAB-Net GCP Training in Sofia

 

On March 9th, CLIN-Net and LAB-Net in collaboration with the European Forum for Good Clinical Practice (EFGCP) organized its 5th face-to-face GCP training in Sofia, Bulgaria. 25 clinical and laboratory investigators from 8 different hospitals in Bulgaria  attended this year’s GCP training.

 
Read full article
 
 
 
 
 
 
 

ECCMID 2017 Highlights: Jesús Rodriguez-Baño

 

Jesús Rodriguez-Baño, Management Board Member of COMBACTE-CARE and Work Package leader of EURECA study, talks about what makes ECCMID a crucial event in tackling AMR, and why is it important for COMBACTE to be there. As of 2018, Dr. Rodriguez-Baño will be the next ESCMID President.

 
Read full article
 
 
 
 
 
 
 

CHU Limoges’ Olivier Barraud: My Passion for Microbiology

 

Olivier Barraud - Clinical Microbiologist at CHU Limoges - is responsible, in the Bacteriology-Virology-Hygiene department, for all COMBACTE studies where CHUL is involved (SAATELLITE, EVADE, REJUVENATE, ANTICIPATE, ASPIRE-SSI). In his blog, Olivier talks about where his passion for Microbiology stemmed, and why he enjoys working for COMBACTE.

 
Read full article
 
 
 
 
 
 
 

ASPIRE-ICU Enrolls 25% of the Subjects

 

In March 2017, COMBACTE-NET's ASPIRE-ICU study has reached an important milestone: 25% enrollment! Currently 536 subjects are enrolled, of the 2000 that are aimed for. Currently, 19 of the 30 selected sites are enrolling subjects in the study cohort, some of which just having started.

 
Read full article
 
 
 
 
 
 
 

SAATELLITE Study Update

 

476 subjects have been enrolled into the COMBACTE-NET SAATELLITE study, of which 142 have been randomized and dosed. There are currently 42 sites active, spread over 9 countries (Belgium, Czech Republic, France, Germany, Greece, Hungary, Spain, Switzerland, and UK).

 
Read full article
 
 
 
 
 
 
 

EVADE Study Update

 

169 patients have been enrolled in COMBACTE-MAGNET's EVADE study, of which 133 have been screen failed and 33 randomized and dosed. In January and February 2017 61 screenings took place. 49 sites have been activated in the following countries: Belgium, Croatia, Czech Republic, France, Greece, Hungary, Portugal and Spain.

 
Read full article
 
 
 
 
 
 
 

ANTICIPATE Study Update

 

As of today, COMBACTE-NET's ANTICIPATE study has been initiated in 27 of 31 sites, of which 22 sites are actively recruiting patients. The team is currently looking into starting backup sites in France, Romania and Germany.

 
Read full article
 
 
 
 
 
 
 

Want to read more?

 
 
 
Check out the newsroom
 
 
 
 
 

Upcoming events

 
 
 
 
 

COMBACTE Country Visit Croatia

 
11/04/2017
2 days
Zagreb, Croatia
 
 
 
 
 
 
 

COMBACTE at ECCMID 2017, Austria

 
22/04/2017
3 days
Vienna, Austria
 
 
 
 
 
 
 

COMBACTE Country Visit Serbia

 
09/05/2017
2 days
Belgrade, Serbia
 
 
 
 
 
 
 

COMBACTE GCP Training Balkans

 
14/06/2017
2 days
Location to be announced
 
 
 
 
 
 
Got great ideas for the newsletter?
 
 
Contact the PMO
 
 
 
 
 
 
 

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.